 | |
| Clinical data | |
|---|---|
| Other names | RMC-6236 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C44H58N8O5S |
| Molar mass | 811.06 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Daraxonrasib (RMC-6236) is an investigational new drug being evaluated by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcinoma (PDAC) containing KRAS G12X mutations. [1] It has received a breakthrough therapy designation from the U.S. Food and Drug Administration. [2]
Daraxonrasib is an orally active, multi-selective RAS inhibitor that uses a novel tri-complex mechanism to target the active, GTP-bound form of RAS proteins, including mutant and wild-type types. Unlike conventional RAS inhibitors, it first binds to the chaperone-like protein cyclophilin A to form a complex, which then attaches to active RAS. This interaction blocks downstream effector binding and inhibits oncogenic signaling. [3]
